Pasithea Therapeutics Corp. (Nasdaq: KTTA) released interim Phase 1 data for its oral MEK inhibitor PAS-004, showing no dose-limiting toxicities ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE